Compare
Becton Dickinson & Co vs Boston Scientific Corp vs 3M Co vs Stryker Corp
| Latest fiscal year | Becton Dickinson & Co BDX | Boston Scientific Corp BSX | 3M Co MMM | Stryker Corp SYK |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $21.84B | $20.07B | $24.95B | $25.12B |
| Revenue growth (YoY) | +8.2% | +19.9% | +1.5% | +11.2% |
| Gross margin | 45.4% (computed) | 69.0% | 39.9% (computed) | 64.0% |
| Operating margin | 11.8% | 18.0% | 18.6% | 19.5% |
| Net margin | 7.7% | 14.4% | 13.0% | 12.9% |
| Net income | $1.68B | $2.89B | $3.25B | $3.25B |
| EPS (Diluted) | $5.82 | $1.94 | $6.00 | $8.40 |
| Operating cash flow | $3.43B | $4.53B | $2.31B | $5.04B |
| Free cash flow | $2.67B | $3.66B | $1.40B | $4.28B |
| Cash & equivalents | $641.00M | $1.97B | n/a | $4.01B |
| Total assets | $55.33B | $43.67B | $37.73B | $47.84B |
| Total liabilities | n/a | n/a | $32.99B | $25.42B |
| Shareholders' equity | $25.39B | $24.47B | $4.75B | $22.42B |
| Return on year-end equity | 6.6% | 11.8% | 68.5% | 14.5% |
| Shares outstanding | n/a | n/a | 530.28M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Becton Dickinson & Co | Boston Scientific Corp | 3M Co | Stryker Corp |
|---|---|---|---|---|
| Latest | $21.84B Ended 2025-09-30 | $20.07B Ended 2025-12-31 | $24.95B Ended 2025-12-31 | $25.12B Ended 2025-12-31 |
| 1 year earlier | $20.18B Ended 2024-09-30 | $16.75B Ended 2024-12-31 | $24.57B Ended 2024-12-31 | $22.59B Ended 2024-12-31 |
| 2 years earlier | $19.37B Ended 2023-09-30 | $14.24B Ended 2023-12-31 | $24.61B Ended 2023-12-31 | $20.50B Ended 2023-12-31 |
| 3 years earlier | $18.87B Ended 2022-09-30 | $12.68B Ended 2022-12-31 | $26.16B Ended 2022-12-31 | $18.45B Ended 2022-12-31 |
| 4 years earlier | $19.13B Ended 2021-09-30 | $11.89B Ended 2021-12-31 | $35.35B Ended 2021-12-31 | $17.11B Ended 2021-12-31 |